NCT01715831View on ClinicalTrials.gov

A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 15, 2013

Primary Completion Date

June 6, 2016

Study Completion Date

June 6, 2016

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

DMARDs

DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.

DRUG

Tocilizumab

Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks

Trial Locations (9)

29043-910

Hospital Universitario Cassiano Antonio Moraes - UFES; Reumatologia, Vitória

40050-410

Santa Casa de Misericordia de Salvador; Reumatologia, Salvador

36036-330

Centro Mineiro de Pesquisa - CMIP, Juiz de Fora

13083-888

Hospital das Clinicas - UNICAMP, Campinas

15090-000

Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto

04026-000

Universidade Federal de Sao Paulo - UNIFESP; Reumatologia, São Paulo

04027-000

Hospital Abreu Sodre - AACD;Reumatologia, São Paulo

04039-004

Hospital Estadual do Servidor Publico; Reumatologia, São Paulo

04266-010

Centro Paulista de Investigacao Clinica - CEPIC, São Paulo

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01715831 - A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 | Biotech Hunter | Biotech Hunter